

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

#### Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Incyte (ruxolitinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Changing Faces</li> <li>Contact</li> <li>Gene People</li> <li>Genetic Alliance UK</li> <li>Let's Face It</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Vitiligo Society</li> <li>Vitiligo Support UK</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>British Association of Dermatologists</li> <li>British Dermatological Nursing Group</li> <li>British Geriatrics Society</li> <li>British Psychological Society</li> <li>Immunodeficiency UK</li> <li>Neonatal and Paediatric Pharmacists Group</li> <li>Primary Care Dermatology Society</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatrics &amp; Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health and Social Care</li> <li>NHS England</li> <li>Welsh Government</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>British Skin Foundation</li> <li>Centre for Evidence Based Dermatology (CEBD), The University of Nottingham</li> <li>Cochrane Skin Group</li> <li>Cochrane UK</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>St John's Institute of Dermatology</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

Final stakeholder list for the evaluation of ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

Issue date: June 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 2

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.